Jasminka Nikolajevic-Sarunac

By Peter Galettis, John Barlow, Jaroslav Boublik, Stefania Capra, Rachel Galettis, Myfanwy Graham, Courtney Hill, Paul Mavor, Jasminka Nikolajevic-Sarunac, Rosemary Richards, Janet Schloss, Melinda Thompson, Linda Truong, Berzenn Urbi, Katrina Weston-Green and Aaron K. Wong

Cannabis medicines are in demand from the public for treating a range of diseases and symptoms; however, clinicians are reluctant to prescribe these products because of limited evidence and prescribing information. To generate this evidence, quality clinical trials of cannabis medicines must be undertaken, yet their design is a complex, often uncharted territory, and involves the cooperation and sharing of knowledge of multiple stakeholders. Before designing a clinical trial, researchers require a clear understanding of the potential therapeutic benefit cannabis medicines may have, the form and formulation of the product, and the dose to be investigated. Researchers must also be aware of the applicable pharmaceutical regulations in the country or jurisdiction where the research is to be undertaken, as well as manufacturing or licensing regulations that may be imposed at the source of the cannabis product. Importantly, collaborations with industry are a key to the successful outcome of cannabis medicines clinical trials. Without funding and sponsorship of clinical trials, the ability to generate quality data will be limited and the evidence for cannabis medicines to be registered as therapeutics lacking. Collaborations between researchers, industry, and regulators, working together in sharing knowledge, are therefore critical to generate high quality cannabis medicines research.

Part of the book: Cannabinoids